利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.027 秒)

    MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF
    7.
    发明申请
    MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF 审中-公开
    神经母细胞瘤的作用机制及其用途

    公开(公告)号：US20110294735A1

    公开(公告)日：2011-12-01

    申请号：US13122783

    申请日：2009-10-30

    申请人： Donald J. Marsh ,  Andrea M. Peier ,  Alessandro Pocai

    发明人： Donald J. Marsh ,  Andrea M. Peier ,  Alessandro Pocai

    IPC分类号： A61K38/16 ,  G01N30/00 ,  A61P3/04 ,  A61P3/10 ,  G01N33/74 ,  A61P3/00

    CPC分类号： G01N33/74 ,  A61K31/425 ,  A61K38/22 ,  A61K45/06 ,  G01N33/566 ,  G01N2333/605 ,  G01N2800/52 ,  A61K2300/00

    摘要： The use of neuromedin U receptor agonists to elevate the levels of GLP-1 and/or PYY in an individual in need of an increase in its levels of GLP-1 and/or PYY is described. Further described is the use of neuromedin U receptor agonists to lower the levels of glucagon in an individual in need of lowered glucagon levels. Thus, methods for elevating GLP-1 and/or PYY and lowering glucagon levels in an individual by administering to the individual compositions comprising a neuromedin U receptor agonist and optionally one or more dipeptidyl peptidase IV (DPP-IV) inhibitors are described. In light of the ability of NMU receptor agonists to raise GLP-1 and PYY levels and lower glucagon levels post-administration, methods are described for evaluating the efficacy of a treatment regimen for a metabolic disorder that includes administering a composition comprising a neuromedin U receptor agonist to an individual comprising measuring the level of glucagon-like peptide 1 (GLP-1) and/or peptide YY (PYY) and/or glucagon in the individual before, during, and after the treatment regimen.

    摘要翻译： 描述了使用神经介肽U受体激动剂来提高需要GLP-1和/或PYY水平增加的个体中GLP-1和/或PYY的水平。 进一步描述的是使用神经介肽U受体激动剂来降低需要降低胰高血糖素水平的个体中胰高血糖素的水平。 因此，描述了通过给予包含神经介肽U受体激动剂和任选的一种或多种二肽基肽酶IV（DPP-IV）抑制剂的个体组合物来降低个体中GLP-1和/或PYY并降低胰高血糖素水平的方法。 鉴于NMU受体激动剂在给药后提高GLP-1和PYY水平和降低胰高血糖素水平的能力，描述了评估治疗方案对于代谢紊乱的功效的方法，其包括施用包含神经介肽U受体的组合物 激动剂，其包括在治疗方案之前，期间和之后测量个体中胰高血糖素样肽1（GLP-1）和/或肽YY（PYY）和/或胰高血糖素的水平。

    Melanin concentrating hormone receptor chimeric and fusion proteins
    9.
    发明授权
    Melanin concentrating hormone receptor chimeric and fusion proteins 失效
    黑色素浓缩激素受体嵌合和融合蛋白

    公开(公告)号：US07029878B2

    公开(公告)日：2006-04-18

    申请号：US10221461

    申请日：2001-03-14

    申请人： Donald J. Marsh

    发明人： Donald J. Marsh

    IPC分类号： C07K14/705 ,  C07K19/00 ,  C12N15/62 ,  G01N33/567

    CPC分类号： C07K14/723 ,  A01K2217/05 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention features melanin concentrating hormone receptor (MCH-R) chimeric and fusion proteins. MCH-R chimeric proteins comprise an MCH-R polypeptide region made up of at least two or more polypeptide regions characteristic of MCH-R found in different species. MCH-R fusion proteins comprise an MCH-R polypeptide region and a fluorescent protein region.

    摘要翻译： 本发明的特征在于黑色素浓缩激素受体（MCH-R）嵌合和融合蛋白。 MCH-R嵌合蛋白包含由在不同种类中发现的MCH-R特征的至少两个或更多个多肽区构成的MCH-R多肽区。 MCH-R融合蛋白包含MCH-R多肽区和荧光蛋白区。